Page last updated: 2024-10-22

aniracetam and Cognition Disorders

aniracetam has been researched along with Cognition Disorders in 3 studies

Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.

Research Excerpts

ExcerptRelevanceReference
"Aniracetam is a pyrrolidinone-type cognition enhancer that has been clinically used in the treatment of behavioral and psychological symptoms of dementia following stroke and in Alzheimer's disease."2.41Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries. ( Nakamura, K, 2002)
"Aniracetam is a member of the nootropic class of drugs, which have possible cognition enhancing effects."2.39Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders. ( Benfield, P; Lee, CR, 1994)
"In the present study, we aimed to evaluate the efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors (ChEIs), in terms of several neuropsychological parameters, in a considerable number of patients with dementia."1.38Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open study. ( Koliaki, CC; Messini, C; Tsolaki, M, 2012)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Koliaki, CC1
Messini, C1
Tsolaki, M1
Lee, CR1
Benfield, P1
Nakamura, K1

Reviews

2 reviews available for aniracetam and Cognition Disorders

ArticleYear
Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders.
    Drugs & aging, 1994, Volume: 4, Issue:3

    Topics: Aged; Aging; Animals; Cognition Disorders; Drug Administration Schedule; Drug Tolerance; Humans; Pyr

1994
Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries.
    CNS drug reviews, 2002,Spring, Volume: 8, Issue:1

    Topics: Acetylcholine; Animals; Biogenic Monoamines; Brain; Brain Diseases; Cognition Disorders; Glutamic Ac

2002

Other Studies

1 other study available for aniracetam and Cognition Disorders

ArticleYear
Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open study.
    CNS neuroscience & therapeutics, 2012, Volume: 18, Issue:4

    Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Drug Therap

2012